Published in J Clin Invest on January 01, 2002
An overview of the serpin superfamily. Genome Biol (2006) 2.14
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost (2007) 1.60
Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest (2003) 1.34
Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med (2005) 1.33
Understanding Dermatan Sulfate-Heparin Cofactor II Interaction through Virtual Library Screening. ACS Med Chem Lett (2010) 0.93
Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood (2008) 0.89
The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone (2012) 0.87
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb Res (2016) 0.86
Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol (2013) 0.85
Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood (2007) 0.85
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest (2007) 0.85
Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood (2005) 0.83
Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II. J Biol Chem (2010) 0.79
COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1. J Thromb Haemost (2011) 0.78
Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem (2010) 0.78
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Thromb Res (2011) 0.77
Unchecked thrombin is bad news for troubled arteries. J Clin Invest (2007) 0.77
A Hexasaccharide Containing Rare 2-O-Sulfate-Glucuronic Acid Residues Selectively Activates Heparin Cofactor II. Angew Chem Int Ed Engl (2017) 0.75
The role of inositol polyphosphate 4-phosphatase 1 in platelet function using a weeble mouse model. Adv Enzyme Regul (2010) 0.75
Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex. Anal Biochem (2011) 0.75
Thrombin signalling and protease-activated receptors. Nature (2000) 9.27
Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood (1997) 1.94
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem (1982) 1.57
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood (2000) 1.47
Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest (2000) 1.44
Chondroitin/dermatan sulfate proteoglycan in human fetal membranes. Demonstration of an antigenically similar proteoglycan in fibroblasts. J Biol Chem (1984) 1.38
Activation of heparin cofactor II by dermatan sulfate. J Biol Chem (1983) 1.33
Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2000) 1.28
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem (1990) 1.26
Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A (2000) 1.21
Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost (1999) 0.99
Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost (1995) 0.96
Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem (2000) 0.90
Role of lysine 173 in heparin binding to heparin cofactor II. J Biol Chem (1991) 0.86
Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem (1989) 0.85
Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood (1985) 0.85
Leukocyte chemoattractant peptides from the serpin heparin cofactor II. J Biol Chem (1991) 0.85
Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost (1995) 0.85
Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost (1999) 0.83
Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem (1987) 0.83
Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. Arterioscler Thromb Vasc Biol (1996) 0.82
Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med (1989) 0.82
Turnover study of heparin cofactor II in healthy man. Thromb Haemost (1985) 0.82
Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res (1996) 0.82
An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest (1992) 0.81
Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet (1985) 0.81
Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet (1985) 0.81
Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. Thromb Res (2000) 0.81
Murine heparin cofactor II: purification, cDNA sequence, expression, and gene structure. Biochemistry (1994) 0.81
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost (1987) 0.81
Heparin cofactor II: a new marker for pre-eclampsia. Blood Coagul Fibrinolysis (1998) 0.80
Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. J Biol Chem (1990) 0.80
Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen. J Lab Clin Med (1999) 0.78
Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol (1986) 0.77
Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56
Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice. Proc Natl Acad Sci U S A (2007) 2.41
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA (2002) 1.83
Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol (2007) 1.74
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation (2008) 1.62
Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation (2005) 1.61
Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation (2005) 1.28
Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res (2007) 1.27
Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2005) 1.22
The contributions of the alpha 2 beta 1 integrin to vascular thrombosis in vivo. Blood (2003) 1.21
Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum (2012) 1.18
Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J Biol Chem (2001) 1.17
Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation (2002) 1.15
P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tissue. Circ Res (2010) 1.14
Ventricular tachycardia associated with transmyocardial migration of an epicardial pacing wire. Ann Thorac Surg (2004) 1.12
Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II. Blood (2011) 1.12
Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood (2004) 1.10
Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance. Arterioscler Thromb Vasc Biol (2006) 1.08
Visceral adipose tissue and atherosclerosis. Curr Vasc Pharmacol (2009) 1.07
Monocyte chemoattractant protein-1 deficiency protects against visceral fat-induced atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.05
A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther (2009) 0.97
Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost (2011) 0.93
Obesity-induced endothelial dysfunction is prevented by deficiency of P-selectin glycoprotein ligand-1. Diabetes (2012) 0.93
Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury. Blood (2008) 0.93
Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood (2005) 0.91
The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele. Mamm Genome (2008) 0.90
Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood (2008) 0.89
Acute myocardial infarction leads to acceleration of atherosclerosis. Atherosclerosis (2013) 0.88
Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ J (2012) 0.88
P-selectin glycoprotein ligand-1 inhibition blocks increased leukocyte-endothelial interactions associated with sickle cell disease in mice. Blood (2012) 0.87
Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease. Br J Haematol (2013) 0.87
Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol (2005) 0.87
The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone (2012) 0.87
Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol (2013) 0.85
Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood (2007) 0.85
Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets (2007) 0.85
P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis (2011) 0.84
Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice. Atherosclerosis (2010) 0.84
Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med (2007) 0.84
Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood (2005) 0.83
Leptin-induced endothelial dysfunction is mediated by sympathetic nervous system activity. J Am Heart Assoc (2013) 0.83
Targeting MCP-1 to reduce vascular complications of obesity. Recent Pat Cardiovasc Drug Discov (2009) 0.82
Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol (2005) 0.82
Blood pressure and vascular effects of leptin in humans. Metab Syndr Relat Disord (2007) 0.82
Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke (2006) 0.81
N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. Glycobiology (2006) 0.81
Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol (2007) 0.80
Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion. Antimicrob Agents Chemother (2014) 0.80
Adiponectin: vascular protection from the fat? Arterioscler Thromb Vasc Biol (2006) 0.79
Competitive bidding for interventional cardiology supplies: lessons learned during round 2. Am J Manag Care (2002) 0.79
Leptin receptor-induced STAT3-independent signaling pathways are protective against atherosclerosis in a murine model of obesity and hyperlipidemia. Atherosclerosis (2010) 0.79
Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood (2014) 0.79
Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. Anal Biochem (2010) 0.78
Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice. Cytotherapy (2011) 0.78
Alpha-galactosidase A in vascular disease. Trends Cardiovasc Med (2007) 0.77
Circulating progenitor and mature endothelial cells in deep vein thrombosis. Int J Med Sci (2013) 0.77
Animal models of thrombosis. Curr Opin Hematol (2009) 0.77
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Thromb Res (2011) 0.77
Dermatan sulfate in tunicate phylogeny: order-specific sulfation pattern and the effect of [→4IdoA(2-sulfate)β-1→3GalNAc(4-sulfate)β-1→] motifs in dermatan sulfate on heparin cofactor II activity. BMC Biochem (2011) 0.77
Valsartan Improves Insulin Sensitivity without Altering Vascular Function in Healthy Overweight Adults without the Metabolic Syndrome. Metab Syndr Relat Disord (2007) 0.76
Haploinsufficiency of E-selectin ligand-1 is associated with reduced atherosclerotic plaque macrophage content while complete deficiency leads to early embryonic lethality in mice. Atherosclerosis (2012) 0.75
Recent advances in understanding endogenous fibrinolysis: implications for molecular-based treatment of vascular disorders. Expert Rev Mol Med (2002) 0.75